MHRA Drug Safety Update: IXCHIQ Chikungunya vaccine – updates to restrictions of use following safety review
Following the completion of a safety review and the recommendations of the Commission on Human Medicines (CHM), the IXCHIQ Chikungunya vaccine is no longer indicated for adults over the age of 60 years, and is contraindicated in all individuals with hypertension, cardiovascular disease, diabetes mellitus, and/or chronic kidney disease. This action follows very rare fatal [...]
The post MHRA Drug Safety Update: IXCHIQ Chikungunya vaccine – updates to restrictions of use following safety review appeared first on Community Pharmacy England.
Recent Comments